J. Carroll
Chairman bei ESPERION THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
J.
Martin Carroll is currently the Chairman at Esperion Therapeutics, Inc., the Lead Director at Catalent Pharma Solutions, Inc., and the Independent Director at Catalent, Inc. He previously served as the President & Chief Executive Officer at Boehringer Ingelheim Pharmaceuticals, Inc., Chairman at Inotek Pharmaceuticals Corp., Independent Director at VIVUS, Inc., Director at Accredo Health, Inc., Independent Director at Mallinckrodt Plc, Director at Boehringer Ingelheim Corp., Director at Pharmaceutical Research & Manufacturers of America, Director at Durata Therapeutics, Inc., and Independent Director at TherapeuticsMD, Inc. He also held the position of Executive VP-Customer Marketing & Sales at Merck & Co., Inc. Mr. Carroll's education includes an MBA from Babson College and an undergraduate degree from Holy Cross College (Indiana).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CATALENT INC
0,02% | 04.12.2023 | 32 186 ( 0,02% ) | 2 Mio $ | 31.03.2024 |
| 15.06.2023 | 41 650 ( 0,02% ) | 111 622 $ | 31.03.2024 |
Aktive Positionen von J. Carroll
| Unternehmen | Position | Beginn |
|---|---|---|
| CATALENT, INC. | Director/Board Member | 29.08.2023 |
| ESPERION THERAPEUTICS, INC. | Chairman | 01.06.2022 |
Catalent Pharma Solutions, Inc.
 Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Director/Board Member | 01.07.2015 |
Ehemalige bekannte Positionen von J. Carroll
| Unternehmen | Position | Ende |
|---|---|---|
| MALLINCKRODT PLC | Director/Board Member | 16.06.2022 |
| THERAPEUTICSMD, INC. | Director/Board Member | 31.12.2021 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Chairman | 01.01.2018 |
| DURATA THERAPEUTICS INC | Director/Board Member | 17.11.2014 |
| VIVUS, INC. | Director/Board Member | 01.09.2014 |
Ausbildung von J. Carroll
| Babson College | Masters Business Admin |
| Holy Cross College (Indiana) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| THERAPEUTICSMD, INC. | Health Technology |
| CATALENT, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Accredo Health, Inc.
 Accredo Health, Inc. Services to the Health IndustryHealth Services Accredo Health, Inc. provides specialty retail pharmacy services in the United States. The company is into the sale of drugs for the recurring treatment of chronic and potentially life threatening diseases. Their services includes specialty retail pharmacy services, clinical services, reimbursement services, delivery services and other support services customized for individual therapies. It was founded in 1980 and is headquartered in Memphis, TN. | Health Services |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Durata Therapeutics, Inc.
 Durata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL. | Health Technology |
